Close

pCDCAR1 ErbB2 h(28BBζ), NK (CAR-NK-3-M331-2BZ)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-ErbB2 (HER2) chimeric antigen receptor(CAR) is constructed for the engineering of NK cell to target human ErbB2. The NK cell is genetically modified through transduction with a lentiviral vector expressing scFv of anti-ErbB2 antibody linked to CD28 transmembrane domain/ endodomain and CD137 (4-1BB), CD3-zeta signaling domains. And the vector product was designed for the treatment of breast carcinomas, ovarian carcinoma .

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • ErbB2
  • Targeting Cell Type
  • NK cell
  • Targeting Diseases
  • Breast carcinomas; ovarian carcinoma
  • Generation
  • Third
  • Vector Name
  • pCDCAR1
  • Vector Length
  • 8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-CD28-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • CD28
    CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatorysignals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells(APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
    41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta,which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • XHM298
  • Host
  • Rabbit
  • Target Species
  • Human
  • Gene Name
  • erb-b2 receptor tyrosine kinase 2
  • Synonyms
  • NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FuncS

Fig.1 Secretion of tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) by CAR T cells assessed by cytometric bead array after 24 h exposure to synovial sarcoma cells.

CAR Construction : FRP5 scFv-41BB-CD28ζ Latest CAR Construction

Fig.1 Secretion of tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) by CAR T cells assessed by cytometric bead array after 24 h exposure to synovial sarcoma cells.

HER2-targeted CAR T cells (blue bars) produced significantly higher levels of TNF-α and IFN-γ than T cells transduced with the empty vector (mock; orange bars). Data are presented as the mean ± standard deviation (SD) of triplicate experiments. The data are representative results from experiments using at least 2 healthy donors. ***P < 0.001.

Murayama, Y., Kawashima, H., Kubo, N., Shin, C., Kasahara, Y., Imamura, M., Oike, N., Ariizumi, T., Saitoh, A., Mihara, K., Umezu, H., Ogose, A., & Imai, C. (2021). Effectiveness of 4-1BB-costimulated HER2-targeted chimeric antigen receptor T cell therapy for synovial sarcoma. Translational oncology, 14(12), 101227.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-ErbB2 scFv h(CD28-41BB-CD3ζ) CARNK, pCDCAR1 (CAR-NK-3-M331-2BZ). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.